Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Entegris Inc (ENTG) Price & Performance

BridgeBio Pharma IncTrade
Entegris IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Entegris Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Entegris Inc trades at $154.4 (market cap $23.24B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays a 0.26% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOENTG
Market Cap
$16.61B$23.24B
Sector
HealthTechnology
52-Week High
$90.17$184.00
52-Week Low
$47.29$68.80
Enterprise Value
$18.16B$26.44B
Dividend Yield
0.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Entegris Inc

ENTG is trading at $152.08, up 6.61% over 24 hours, near its consensus price target of $181.17. The stock shows bullish momentum with strong earnings beats in recent quarters, driven by AI-related semiconductor demand. Technical indicators suggest a bullish trend, though RSI hints at overbought conditions. Revenue growth and margin expansion are supported by increasing chip complexity and purity solutions demand.

Outlook remains positive with analyst consensus favoring Buy (66.67%), but high valuation multiples like P/E of 76.04 pose risks. Key opportunities include sustained AI-driven growth, while risks involve valuation sensitivity and semiconductor cycle volatility. The company's cash flow stability and strategic positioning in advanced segments support long-term potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Entegris Inc

Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.

Read more on ENTG